ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch--
--All Clinical Programs Progressing on Track--
--Company Reiterates Guidance of at Least 30% Revenue Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs--
https://finance.yahoo.com/news/insmed-reports-second-quarter-2022-113000262.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.